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Available online 09 February 2016DEP-domain containing 5 (DEPDC5), encoding a repressor of the mechanistic target of rapamycin complex 1
(mTORC1) signaling pathway, has recently emerged as a major gene mutated in familial focal epilepsies and
focal cortical dysplasia. Here we established a global knockout rat using TALEN technology to investigate
in vivo the impact of Depdc5-deﬁciency. Homozygous Depdc5−/− embryos died from embryonic day 14.5 due
to a global growth delay. ConstitutivemTORC1 hyperactivationwas evidenced in the brains and in cultured ﬁbro-
blasts of Depdc5−/− embryos, as reﬂected by enhanced phosphorylation of its downstream effectors S6K1 and
rpS6. Consistently, prenatal treatment with mTORC1 inhibitor rapamycin rescued the phenotype of Depdc5−/−
embryos. Heterozygous Depdc5+/− rats developed normally and exhibited no spontaneous electroclinical sei-
zures, but had altered cortical neuron excitability and ﬁring patterns. Depdc5+/− rats displayed cortical cytome-
galic dysmorphic neurons and balloon-like cells strongly expressing phosphorylated rpS6, indicative of mTORC1
upregulation, and not observed after prenatal rapamycin treatment. These neuropathological abnormalities are
reminiscent of the hallmark brain pathology of human focal cortical dysplasia. Altogether, Depdc5 knockout
rats exhibit multiple features of rodent models of mTORopathies, and thus, stand as a relevant model to study
their underlying pathogenic mechanisms.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
DEPDC5
Familial focal epilepsy
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mTOR
Rapamycin
Knockout1. Introduction
DEP-domain containing 5 (DEPDC5) is the most common known
cause of familial focal epilepsies (nearly 70 unrelated cases described
so far). Germline heterozygous inactivating DEPDC5 mutations are re-
ported in a broad spectrum of focal epileptic syndromes includingoelle épinière (ICM), Hôpital
ce.
.com).
. This is an open access article underfamilial focal epilepsy with variable foci (FFEVF; OMIM 604364), auto-
somal dominant nocturnal frontal lobe epilepsy (ADNFLE; OMIM
600513), familial temporal lobe epilepsy (FTLE; OMIM 600512) and
rare Rolandic epilepsies (OMIM 245570) (Dibbens et al., 2013; Ishida
et al., 2013; Lal et al., 2014; Martin et al., 2014; Picard et al., 2014). Pa-
tients present focal seizures with variable age at onset, typically during
childhood. Brain MRI is usually normal, although within families, some
individuals may have a focal cortical dysplasia (FCD; OMIM 607341)
(Baulac et al., 2015; Scerri et al., 2015; Scheffer et al., 2014), which is
the most common cause of severe, drug-resistant childhood epilepsy.
FCD is a malformation of cortical development characterized by cortical
dyslamination and the presence of dysmorphic neurons (FCD type IIa)
and balloon cells (FCD type IIb) (Blumcke et al., 2011). Recently,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tients with FCD or hemimegalencephaly (D'Gama et al., 2015).
DEPDC5 does not encode a membrane ion channel, unlike most
other epilepsy genes. Instead, DEPDC5 acts in vitro as a GTPase-
activating protein for RagA/B, and forms part, together with NPRL2
and NPRL3, of the GATOR1 complex to inhibit the mechanistic target
of rapamycin complex 1 (mTORC1) pathway (Bar-Peled et al., 2013;
Panchaud et al., 2013). Recently, mutations in NPRL2 and NPRL3 have
also been reported in familial focal epilepsies associated with FCD
(Ricos et al., 2016; Sim et al., 2016). The mTORC1 pathway is a
major and ubiquitous signaling cascade that regulates multiple
cellular processes including cell growth, proliferation and protein
synthesis (Laplante and Sabatini, 2012). It is dysregulated in several
neurological disorders associated with neurodevelopmental cortical
malformations and intractable seizures (Lim and Crino, 2013),
including FCD, hemimegalencephaly and tuberous sclerosis complex
(TSC; OMIM 191100 and 613254) due to mutations in TSC1 and TSC2
genes, encoding inhibitors of the mTORC1 pathway. Numerous
rodent models of TSC have been engineered and recapitulate part
of the neuropathological features of the disease (Bateup et al.,
2013; Meikle et al., 2007). Knockout mice of Depdc5 partners,
Nprl2 and Nprl3 have also been recently generated, but have not
been explored at the neurological level (Dutchak et al., 2015;
Kowalczyk et al., 2012).
To date, the in vivo function of Depdc5 inmammals and its role in ep-
ilepsy and corticalmalformations remain unknown. Here, we generated
a global knockout rat of Depdc5 to model its loss-of-function and inves-
tigate the resulting consequences in the brain.2. Materials and methods
2.1. Animals
Depdc5em1kyo andDepdc5em2kyo ratswere generated and deposited at
the National Bio Resource Project Rat in Japan (www.anim.med.kyoto-
u.ac.jp/nbr). Animal care and experimental procedures were approved
by the Frenchministry of research (authorization number 75-1319, pro-
ject number 03539.02). All efforts were made to minimize the number
of animals needed and their suffering.2.2. TALEN-mediated genome editing in rats
A pair of TALENs targeting exon 2 of rat Depdc5 (Ensembl:
ENSRNOT00000085788) was designed and constructed using a two-
step assembly method with a Platinum Gate kit as previously reported
(Sakuma et al., 2013). The target sites were located immediately down-
stream of the ATG start codon. TAL Effector Nucleotide Targeter 2.0
(https://tale-nt.cac.cornell.edu/) did not predict off-target site. We se-
lected the Fisher 344 (F344) rat strain since we previously proved that
it is a pertinent model for genetically-determined epilepsies, as exem-
pliﬁed by the Kcna1 (Ishida et al., 2012), Scn1a (Mashimo et al., 2010)
or Lgi1 (Baulac et al., 2012) mutant rats. TALENs were microinjected
into fertilized eggs of F344, and then transferred into the oviducts of
pseudopregnant Wistar female rats, as previously described (Mashimo
et al., 2013). Genomic DNA of founder rats was extracted from tail
biopsies. TALEN target site was ampliﬁed using the following primers:
forward 5′-AGCCTGACATTCTCGCTGTT-3′ and reverse 5′-TCTTGCCCCA
CTCATTTACC-3′. Successful germline transmission was conﬁrmed by
DNA sequencing of ﬁrst backcross generation rats. These rats were
backcrossed ﬁve times with wildtype F344 rats. Genotypes were
assessed by the analysis of the PCR products from tail DNA with a
high-resolution electrophoresis caliper system. A 267 bp band was de-
tected for wildtype, a 279 bp band for Depdc5em1kyo mutant and a
251 bp band for Depdc5em2kyo mutant.2.3. Assessment of embryo vitality
Pregnant ratswere injectedwith lethal dose of pentobarbital sodium
(50 mg/kg, i.p.). Embryos were collected by cesarean-section and kept
on awarmingpad tomaintain their body temperature at 37 °C. To assess
vitality of embryos aged E12.5 to E16.5, heartbeatwas directly observed
under a binocular microscope. For E21.5 embryos, cardiac activity was
assessed by electromyogram (Neurosoft).
2.4. Rapamycin injection
Rapamycin (LC laboratories) was dissolved at 20 mg/ml in 100%
ethanol and stored at−20 °C. Before use, it was diluted to 1 mg/ml
in 0.25% Tween 80 and 0.25% polyethylene glycol 300 in PBS. A single
dose of 1 mg/kg rapamycin was intraperitoneally injected to preg-
nant Depdc5+/− dams at E13.5 as previously reported (Ma et al.,
2014).
2.5. Rat embryonic ﬁbroblast culture
Rat embryonic ﬁbroblasts (REFs) were collected at E13.5 from
Depdc5+/− interbreeding and cultured in standard medium:
Dulbecco's Modiﬁed Eagle's Medium (DMEM) (Life Technologies)
containing 10% fetal bovine serum and 1% penicillin/streptomycin.
Rapamycin (20 nM dissolved in 100% ethanol) was added to Earle's
Balanced Salt Solution (EBSS) during the whole starvation period until
the harvesting of REFs.
2.6. Cytoﬂuorometric rat embryonic ﬁbroblast size analysis
1 × 106 REFs (passage 6 to 8) were seeded in 100 mm diameter
dishes, allowed to proliferate overnight, and then cultured in
DMEM without serum for 48 h and starved in EBSS for 3 h. REFs
were harvested by gentle trypsinization, washed twice in PBS and
ﬁxed in 80% ethanol in PBS. After overnight ﬁxation at −20 °C, ﬁxed
cells were washed in PBS, resuspended in DNA staining solution con-
taining 0.20 μg/ml propidium iodide, 100 μg/ml RNaseA and 20 mM
EDTA in PBS, and incubated for 30 min at 37 °C. REF soma sizes
were analyzed by ﬂow cytometry: the mean cytoﬂuorometric for-
ward scatter (FSC) of minimum 800 stained cells was determined
by gating on propidium iodide ﬂuorescence using BD Biosciences
FACSCalibur with CellQuest software as previously described (Acosta-
Jaquez et al., 2009).
2.7. Western blots
Whole heads of E12.5 embryos were ﬂash-frozen in liquid nitrogen,
homogenized with lysing matrix D (MP Biomedicals) in cell lysis buffer
(Cell Signaling) containing phosphatase inhibitors and protease inhibi-
tors (Roche). REFs (passage 5) were nutrient-starved with EBSS for
7 h, washed with PBS and then lysed in the same lysis buffer. Similar
amount of protein was loaded in each lane in 3–8% Tris–acetate gel for
Depdc5 and 10% Bis-Tris–acetate gel (NuPAGE) for phosphorylated
S6K1 and rpS6. Western blots were done using the following primary
antibodies: anti-DEPDC5 (Cell Signaling, #H6302, 1/100), anti-actin
(Sigma Aldrich, #A2066, 1/1000), anti-phosphorylated S6K1 (Thr389)
(Cell Signaling, #9205, 1/250) and anti-phosphorylated rpS6 (Ser240/
244) (Cell Signaling, #5364, 1/4000). Signal quantiﬁcation was per-
formed using MultiGauge software (Fuji Film).
2.8. Histology and immunohistochemistry
Whole embryos (E15)were rapidly removed from their chorion and
ﬁxed overnight in 4% paraformaldehyde (PFA) in 0.1 M phosphate buff-
er (PB). Postnatal day (P) P11 and 4 week old rats were injected with a
lethal dose of pentobarbital sodium (50 mg/kg, i.p.) and perfused with
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in 30% sucrose in PB 0.1 M, and then stored at−80 °C. Cryostat whole
embryo sagittal sections (16 μm thick), P11 brain coronal-cut sections
(20 μm thick) and 4 week brain coronal-cut sections (35 μm thick)
were collected. To visualize whole embryo gross anatomy and adult
brain cortical architecture, sections were stained with Nissl-staining
and hematoxylin–eosin using standard techniques. Cell size was deter-
mined from Nissl-stained brain sections using NDP.view2 viewer
software (Hamamatsu Photonics) to analyze digital slide ﬁles. After
manual drawing of cell margins, we measured the area from at least
50 large layer IV–V cells. The largest 30 cells per animal were included
in the measurements for statistical comparison.
Immunostaining experiments were performed using standard
procedure with primary anti-phosphorylated rpS6 Ser240/244 anti-
body (Cell Signaling, #5364, 1/200) and secondary ﬂuorescent anti-
rabbit Alexa 488 antibody (Invitrogen, 1/1000). Nuclei were stained
with DAPI. Images were acquired and analyzed through the
Nanozoomer software (Hamamatsu photonics). TUNEL assays were
performed using In Situ Cell Death Detection Kit (Roche) according to
the manufacturer's instructions and images were acquired using a
Zeiss apotome.2.9. In vivo intracellular electrophysiology
Adult rats were anesthetized with 40 mg/kg sodium pentobarbital
and 50mg/kg ketamine (i.p.). Incision and pressure points were repeat-
edly inﬁltrated with 2% lidocaine. In line with behavioral EEG experi-
ments (Supplementary data), a small craniotomy was made above the
parietal association cortex, allowing combined intracellular and
electrocorticographic (ECoG) recordings. The rats were subsequently
maintained in a narcotized and sedated state, monitored with the
ECoG and heartbeat rate, by injections of fentanyl (3 μg/kg, i.p.) repeat-
ed every 20–30 min as previously described (Polack et al., 2009). Rats
were paralyzed with gallamine triethiodide (40 mg/2 h, i.m.) and artiﬁ-
cially ventilated. Body temperature was maintained at 37 °C with a ho-
meothermic blanket.
ECoG signals were ampliﬁed by a differential AC ampliﬁer (Model
1700; A-M Systems), band pass ﬁltered at 1 Hz–1 kHz, and digitized at
3 kHz (Power1401; Cambridge Electronic Design). Intracellular glass
micropipettes were ﬁlled with 2 M potassium acetate (60–80 MΩ).
Current-clamp recordings were ampliﬁed using an Axoclamp 900A
ampliﬁer (Molecular Devices) in bridge mode, ﬁltered at 6 kHz, and
digitized at 20 kHz. Recordings were obtained from pyramidal neurons
located at depths ranging from 415 to 1525 μm below the cortical
surface (Paxinos, 2005). All data were acquired and analyzed using
Spike2 software (Spike2 version 7.16; Cambridge Electronic Design).
Neuronswere labeled with neurobiotin (Vector Laboratories) added
to the intrapipette solution (1%). At the end of experiments, rats were
deeply anesthetized with pentobarbital (200 mg/kg, i.p.) and
transcardially perfused with 0.3% glutaraldehyde-4% PFA in PB. The
morphology of stained neurons was revealed histochemically as de-
scribed previously (Polack and Charpier, 2006).
To generate ﬁring frequency versus injected current (F–I) relation-
ships, the ﬁring rate was measured in response to 500 ms depolarizing
current pulses of increasing intensity. Each current intensity was ap-
plied 3–10 times and the correspondingﬁring responseswere averaged.
As previously described (Mahon and Charpier, 2012; Paz et al., 2009),
we applied linear regressions to F–I curves and determined the thresh-
old current for action potential (AP) generation, extrapolated as the x-
intercept of the linear ﬁt, and the neuronal gain, deﬁned as the slope
of the F–I curve. The spontaneousﬁring rate and averagemembrane po-
tential was calculated from continuous recordings of at least 40 s. Mem-
brane input resistance was calculated as the slope of the linear portion
of the voltage–current relationships (500 ms hyperpolarizing pulses of
increasing intensity) and the membrane time constant was derivedfrom an exponential decay ﬁt applied to the initial part of the current-
induced hyperpolarizations.
Neuronal physiological classes were established as in previous
studies (Degenetais et al., 2002; Nunez et al., 1993). Intrinsic bursting
cells were characterized either by an initial high-frequency (typical-
ly N200 Hz) burst of APs followed by a relatively tonic ﬁring or by
consecutive bursts of APs. Regular spiking slow adapting neurons ex-
hibited a sustained discharge of APs with a low frequency adaptation
along the current step, while regular spiking fast adapting cells
responded to high intensity (typically N0.6 nA) current step by an initial
sequence of 3–8 APs restricted to the ﬁrst 50–100 ms of the response
followed by a depolarizing plateau with few or no APs.
2.10. Statistical analysis
Statistical analyses were done with GraphPad and SigmaStat
software. The results are presented as mean ± SEM. Normality was
assessed by Kolmogorov–Smirnov normality test. Comparisons be-
tween two groups were performed by unpaired two-tailed Student's
t-test for parametric data and by Mann–Whitney test for non-
parametric data. Comparisons between multiple groups were per-
formed by 1-way ANOVA with Tukey's multiple comparison test as
post-hoc analysis for parametric data and by a Kruskal–Wallis test for
non-parametric data.
3. Results
3.1. Generation of a global Depdc5 knockout rat
DEPDC5-related epilepsies are likely to result from a loss-of-function
since the majority of mutations leads to a premature stop codon,
targeted by nonsense-mediated mRNA decay (Ishida et al., 2013;
Picard et al., 2014). We used transcription activator-like effector nucle-
ase (TALEN)-mediated genome editing to generate a global Depdc5
knockout rat and to investigate the effects of Depdc5-deﬁciency in vivo.
TALEN mRNAs targeting exon 2 of rat Depdc5 were microinjected into
fertilized eggs of Fisher 344 (F344) rats, to yield two founder mutant
rats named Depdc5em1kyo (c.40_44delins17/p.Gly15*) and Depdc5em2kyo
(c.39_55delinsT/p.Lys13fs*8) (Fig. 1A). Successful gene targeting was
conﬁrmed by Western blot analysis of whole head lysates from living
embryos, with an anti-Depdc5 antibody. Depdc5 protein was absent in
homozygousDepdc5em1kyo andDepdc5em2kyo rats, and expressionwas re-
duced in heterozygous littermates (Fig. 1B). The homozygous knockout
Depdc5em1kyo and Depdc5em2kyo rat strains were therefore indifferently
referred to as Depdc5−/−, and the heterozygous as Depdc5+/−.
3.2. Embryonic lethality and growth delay in Depdc5−/− rats
While Depdc5+/− rats interbred, Depdc5−/− pups were never ob-
served at birth. Deletion of both alleles resulted in in utero lethality, as
reported in knockout rodents of other genes of the mTORC1 pathway
such as Tsc1 (Kobayashi et al., 2001) and Tsc2 (Onda et al., 1999;
Rennebeck et al., 1998). We assessed the timing of the embryonic le-
thality by collecting embryos from Depdc5+/− interbred rats at gesta-
tion dates between E12.5 and E21.5 (Table 1). All Depdc5−/− embryos
were alive until E13.5. However, at E14.5, E15.5 and E16.5, only 50%
(7/14), 40% (2/5) and 21% (3/14) of living Depdc5−/− embryos were
observed. Depdc5−/− embryos at E13.5-E16.5 were smaller than
Depdc5+/+ and Depdc5+/− littermates (Fig. 1C). With less developed
limbs and optic vesicles, we conclude that global growth delay precedes
embryonic lethality observed from E14.5.
Measurements of whole-mount sections from living E14.5 embryos
conﬁrmed that Depdc5−/− embryos are smaller (n = 7; 6.9 ±
0.2 mm) than Depdc5+/+ embryos (n = 7; 7.9 ± 0.2 mm) (P b 0.01;
Mann–Whitney test) (Fig. 1D). TUNEL assays revealed the presence of
apoptotic cells in the liver of E14.5 Depdc5−/− embryos (Fig. 1E),
Fig. 1. Depdc5−/− rats die embryonically and present growth delay. (A) DNA sequences of wild-type and TALEN-mutated Depdc5 sequences. TALE: transcription activator-like effector,
Fokl: restriction endonuclease FokI. TALE binding sequences are shown in blue. Deleted bases are framed, and inserted bases are indicated by the red letters. Depdc5em1kyo strain carries
a deletion of 5 bp and an insertion of 17 bp, and Depdc5em2kyo a deletion of 17 bp and an insertion of 1 bp at the targeted site. (B) Western blots of head lysates (60 μg of protein each)
from living embryonic day 12.5 (E12.5) embryos derived from Depdc5em1kyo and Depdc5em2kyo strains with Depdc5 and actin antibodies. The Depdc5 speciﬁc band is indicated by an
arrow, the upper band is nonspeciﬁc. (C) Representative picture of embryos from three litters at E13.5, E14.5 and E16.5. Picture of E16.5 embryo is composed of two images. Scale bar:
2 mm. (D) Representative Nissl-stained whole body sagittal sections of living E14.5 (Depdc5+/+, n = 7; Depdc5−/−, n = 7) embryos. Scale bar: 1 mm. (E) Representative images of
TUNEL staining on fetal liver from living E14.5 (Depdc5+/+, n = 3; Depdc5−/−, n = 3) embryos. Scale bar: 100 μm. (F) Higher magniﬁcation view of brain regions on Nissl-stained
sections. From left to right panel: neocortex, lateral ventricle and ganglionic eminence. Histogram indicates quantiﬁcation of neocortical thickness (indicated by black arrows), lateral
ventricular and ganglionic eminence surfaces (dashed-lines). Scale bar: 50 μm, 500 μm and 250 μm respectively. Number of embryos is indicated in brackets. Error bars represent
mean ± SEM. n.s., not signiﬁcant; *P b 0.05; **P b 0.01 (Mann–Whitney test).
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of premature death. This result reveals that Depdc5 plays an important
role in liver development, and recalls the liver defects observed inknockout mice of Depdc5 partners, Nprl2 and Nprl3 (Dutchak et al.,
2015; Kowalczyk et al., 2012) acting in the GATOR1 complex. The cere-
bral neocortical structures of embryonic Depdc5−/− rats were also
Table 1
Viability of Depdc5−/− embryos according to age.
Age
Number of embryos
Total +/+ +/− −/−
E12.5 28 7 15 6 (100%)
E13.5 44 15 21 8 (100%)
E14.5 75 24 37 14 (50%)
E15.5 51 17 29 5 (40%)
E16.5 95 16 65 14 (21%)
E21.5 31 4 25 2 (0%)
P5 96 35 61 0 (0%)
E, embryonic day; P, postnatal day; numbers in parentheses refer to percentage of living
Depdc5−/− embryos with heartbeat detected.
Fig. 2.mTORC1 pathway is upregulated in Depdc5−/− embryos. (A) Schema of the Depdc5-m
treated with rapamycin (Depdc5+/+, n = 14; Depdc5+/−, n = 23; Depdc5−/−, n = 4). Scale b
treated or not with prenatal rapamycin. (C) Top panel: Western blot of brain lysates (30 μg
and actin antibodies. Bottom panel: Histogram of densitometry analysis of pS6 normalized wi
(15 μg of protein) derived from littermate embryos with phosphorylated S6K1 on Thr389 (p
starvation, with or without rapamycin. Bottom panel: histogram of densitometry analysis o
expressed as mean cytoﬂuorometric forward scatter (FSC), in standard or amino acid starva
embryos is indicated in brackets. Error bars represent mean ± SEM. a.u., arbitrary units; n.s.
comparison post-hoc tests).
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development in humans. Analysis of Nissl-stained whole-embryo sec-
tions revealed the neocortexwas thinner and the surfaces of both lateral
ventricles and ganglionic eminences were smaller in Depdc5−/− embry-
os than in their Depdc5+/+ littermates (Fig. 1F).3.3. Prenatal rapamycin rescues growth delay and embryonic lethality in
Depdc5−/− rats
Previous in vitro studies have reported that Depdc5 acts as a repres-
sor of the mTORC1 signaling pathway (Fig. 2A) (Bar-Peled et al., 2013;
Panchaud et al., 2013). IfmTORC1 pathwaywere involved in the embry-
onic lethality ofDepdc5−/− rats, prenatal administration of themTORC1
inhibitor rapamycin might rescue their phenotype. We injected a singleTORC1 signaling pathway. (B) Top panel: Representative picture of living E21.5 embryos
ar: 1 cm. Bottom panel: Histogram showing the percentage of living Depdc5−/− embryos
of protein) of E12.5 littermate embryos with phosphorylated rpS6 on Ser240/244 (pS6)
th actin from two independent Western blots. (D) Top panel: Western blot of REF lysates
S6K1), phosphorylated rpS6 on Ser240/244 (pS6) and actin antibodies after amino acid
f pS6K1 and pS6 normalized with actin from above Western blot. (E) REF soma sizes,
tion conditions from two independent cytoﬂuorometric REF sizes analysis. Number of
, not signiﬁcant; *P b 0.05; **P b 0.01; ***P b 0.001 (1-way ANOVA and Tukey's multiple
185E. Marsan et al. / Neurobiology of Disease 89 (2016) 180–189dose of rapamycin (1 mg/kg) to pregnant Depdc5+/− dams at E13.5, as
previously reported in a Tsc1 knockout mouse model (Ma et al., 2014).
The proportion of living Depdc5−/− embryos increased from 50% to
83% at E14.5 with this treatment. At the projected birth date E21.5,
31% (4/13) of living Depdc5−/− rats were obtained after prenatal
rapamycin treatment (Fig. 2B, bottom). The body length of E21.5 res-
cued Depdc5−/− embryos (n= 4; 3.8 ± 0.2 cm) was similar to that of
Depdc5+/+ (n = 10; 3.7 ± 0.3 cm) and Depdc5+/− (n = 11; 3.9 ±
0.3 cm) littermate embryos (P N 0.5; Kruskal–Wallis test), indicating
that rapamycin also reversed growth delay. While rapamycin enhanced
embryonic survival of Depdc5−/− rats, they showed global edema, and
died shortly after birth from impaired maternal–pup interaction.
Rapamycin treatment earlier or later than E13.5 did not improve
Depdc5−/− embryo survival (data not shown). The appearance and
body length of treated Depdc5+/+ and Depdc5+/− rats were similar to
those of untreated littermates, indicating that rapamycin had no major
adverse effects on control rats (Fig. 2B, top). This results provided evi-
dence thatmTORC1 pathway is involved in growth delay and embryon-
ic lethality in Depdc5−/− embryos.
To further validate an mTORC1 activity-dependent mechanism, we
assessed at the molecular level whether mTORC1 is upregulated in the
brains of Depdc5−/− embryos. Thus we monitored by Western blot
mTORC1 activation through the phosphorylation state of one of its
downstream effector, the ribosomal protein S6 (rpS6, on Ser240/244).
rpS6 phosphorylation level was signiﬁcantly enhanced in brain lysates
of E12.5 Depdc5−/− embryos compared to Depdc5+/+ and Depdc5+/−
littermates, and tended to be higher in Depdc5+/− than in Depdc5+/+
embryos (Fig. 2C). This indicates constitutive activation of mTORC1 in
the brains of Depdc5-deﬁcient embryos with a gene dosage effect such
that levels of phosphorylated rpS6 are higher when both copies of
Depdc5 are deleted.
3.4. Upregulation ofmTORC1 inDepdc5−/− cultured ﬁbroblasts after amino
acid starvation
mTORC1 pathway is sensitive to amino acid starvation. Since in vitro
data frommammalian cell lines suggests this sensitivity is abolished by
Depdc5 knockdown (Bar-Peled et al., 2013), we examined the effect of
Depdc5-deﬁciency on primary rat embryonic ﬁbroblasts (REFs). REFs
derived from Depdc5+/− interbreeding let us compare mTORC1 activity
in standard or amino acid-deprived culturemedia.mTORC1 activitywas
monitored by the phosphorylation of two downstream effectors: p70S6
kinase 1 (S6K1, on Thr389) and the S6K1 substrate rpS6 (on Ser240/
Ser244) as previously reported (Dutchak et al., 2015; Efeyan et al.,
2014; Liang et al., 2014). In standard medium, Western blots of REF
lysates indicated that phosphorylation levels of S6K1 and rpS6 were
similar across genotypes (data not shown). However, after amino acid
starvation, phosphorylation states of both S6K1 and rpS6 were consis-
tently increased in REF lysates derived from Depdc5−/− embryos com-
pared to those from Depdc5+/+ and Depdc5+/− embryos (Fig. 2D).
Rapamycin treatment of REFs derived from Depdc5−/− embryos
abolished S6K1 and rpS6 phosphorylation, conﬁrming that Depdc5 neg-
atively regulates mTORC1 activity. We also compared mTORC1 activity
in REFs derived from Depdc5+/− embryos to REFs derived from
Depdc5+/+ embryos to assess the effect of the lack of one copy of
Depdc5 on the pathway activity. Semi-quantiﬁcation of Western blot
suggested a tendency to increased phosphorylation states of S6K1 and
rpS6 in REFs derived from Depdc5+/− compared to Depdc5+/+, but did
not reach signiﬁcant levels (Fig. 2D). This result is in line with the data
obtained above in brain lysates (Fig. 2C), showing robust mTORC1
upregulation in Depdc5−/− embryos, and more subtle effects in
Depdc5+/− embryos. A similar upregulation was obtained in REFs
derived from a knockout mouse for Nprl2 (Dutchak et al., 2015), one
of the two Depdc5 partners in the GATOR1 complex.
Acting via S6K1 and rpS6, mTORC1 is a pivotal regulator of cell size.
We therefore assessed the impact of an mTORC1 upregulation on thesoma size of REFs derived from Depdc5+/+, Depdc5+/− and Depdc5−/−
embryos, in standard or amino acid starvation condition using ﬂow
cytometry analysis. In standard medium, REF soma sizes did not differ
signiﬁcantly between genotypes. After amino acid starvation, both
Depdc5+/+ and Depdc5+/− derived REFs were reduced in size while
Depdc5−/−derived REFs remained unchanged (Fig. 2E). These data indi-
cate that Depdc5 is necessary to control the cell growth by repressing
mTORC1 pathway during amino acid starvation.
3.5. Brain cortical structural abnormalities in Depdc5+/− rats
HeterozygousDepdc5+/− rats displayed nodifferences in gross anat-
omy, fertility and rates of weight gain compared to control littermates
(Supplementary data, Fig. 1A). Some inactivating deletions in DEPDC5
may be associated with ovarian cancers and glioblastomas (Cancer
GenomeAtlas: http://cancergenome.nih.gov/). Besides, TSC patients de-
velop tumors associatedwith an increasedmTORC1activity (Onda et al.,
1999).We therefore askedwhether Depdc5-deﬁciency promotes tumor
development. No evidence for tumors was apparent in Depdc5+/− rats
whole body at ages greater than 12 months (n= 8). Furthermore, we
detected no differences between Depdc5+/+ and Depdc5+/− littermate
rats survival (up to 18 months).
We next assessed possible defects in brain cortical architecture of
Depdc5+/− rats, since heterozygousDEPDC5mutationsmay cause corti-
cal malformation such as FCD type II in humans (Baulac et al., 2015;
D'Gama et al., 2015; Scerri et al., 2015) with an increased cortical thick-
ness, blurred gray/whitematter demarcation and cortical dyslamination
as well as dysmorphic neurons in FCD type IIa, and balloon cells in FCD
type IIb (Blumcke et al., 2011).We found that the brain-to-body weight
ratios of Depdc5+/+ and Depdc5+/− rats were similar (Supplementary
data, Fig. 1B). Nissl-staining of coronal brain sections of Depdc5+/−
rats revealed no major defects in the structural brain organization at
4 weeks (Fig. 3A) and 23 weeks (data not shown). Cerebral cortical
thickness did not differ between Depdc5+/+ (n = 6, 1.22 ± 0.01 mm)
andDepdc5+/− (n=6, 1.21± 0.01mm) rats (P N 0.05; Mann–Whitney
test), neither in gray/white matter boundaries (Fig. 3A). In contrast, the
delimitations between the six cortical layers were less distinct in
Depdc5+/− rats, particularly between layers I–II (ectopic neurons were
observed in layer I) and V–VI (Fig. 3B). These aberrantly positioned
cells suggest that neuronal migration was perturbed because of
Depdc5 haploinsufﬁciency. Furthermore, Nissl and hematoxylin &
eosin staining revealed the presence of enlarged cells throughout the
cortex of Depdc5+/− rats, especially in layers IV–V (approximately
15 cells/mm2). These cells consisted of both balloon-like cells resem-
bling those seen in FCD type IIb, with no Nissl substance and an eosino-
philic cytoplasm (Fig. 3C, top), and of cytomegalic dysmorphic neurons,
with an aggregated Nissl substance displaced towards the cell mem-
brane, as seen in FCD type IIa and IIb (Fig. 3C, middle). Balloon-like
cells and cytomegalic dysmorphic neurons were never observed in
Depdc5+/+ littermates. To conﬁrm a difference in neuronal cell size,
we measured the soma size of pyramidal neurons in cortical layers IV–
V fromNissl-stained sections. The soma size of the cytomegalic dysmor-
phic neurons present in cortical layers IV-V of Depdc5+/− rats were sig-
niﬁcantly greater than the largest pyramidal cell inDepdc5+/+ rats from
same layers, with an average area size increase of ~30% (Fig. 3C,
bottom).
3.6. Effects of rapamycin treatment on cytomegalic dysmorphic neurons
Are these cytomegalic dysmorphic neurons linked to mTORC1
upregulation? We pursued this question by immunostaining for phos-
phorylated rpS6 (on Ser240/244) in brain sections from 4 week-old
Depdc5+/+ and Depdc5+/− rats. A basal level of rpS6 phosphorylation
was detected in normal-appearing (non-cytomegalic) pyramidal neu-
rons from Depdc5+/+ and Depdc5+/− rats (Fig. 3D, left). In contrast,
phosphorylated rpS6 staining of the majority of cytomegalic
Fig. 3. Depdc5+/− rats develop brain cortical abnormalities. (A to D) Representative brain anatomy of 4-week old littermate rats (Depdc5+/+, n = 3; Depdc5+/−, n = 3). (A) Nissl-stained
whole-brain coronal sections showing the organization of cortical layers. Scale bar: 1 mm. (B) Higher magniﬁcation of panel A showing the organization of cortical layers, with
enlargement of boundaries between layers I–II and V–VI. scale bar: 100 μm. (C) Top panel; Hematoxylin–eosin staining showing dysmorphic neurons (black arrows) and balloon-like
cells (white arrows) in cortical layer V. Middle panel; Nissl staining showing dysmorphic neurons (black arrows) in cortical layer V. Scale bar: 25 μm. Bottom panel; quantitative
neuronal size analysis from cortical layers IV–V of 4-week old littermate rats (n = 30 cells per animal). Student's t-test was used. (D) Immunohistochemistry of enlarged cells with
intense phosphorylated rpS6 on Ser240/244 (pS6) signals in Depdc5+/− rats. Scale bar: 25 μm. (E) Representative brain anatomy of P11 old (Depdc5+/−, n = 3; Depdc5+/− treated
with rapamycin, n = 2) rats. Left and middle panel; Nissl staining showing dysmorphic neurons (black arrows) in Depdc5+/− and normal appearing neurons in Depdc5+/− treated
with rapamycin in cortical layer V. Scale bar: 20 μm. Right panel; quantitative neuronal size analysis from cortical layers IV–V of P11 rapamycin untreated and treated rats (n = 30
cells per animal). Kruskall–Wallis test was used. Number of cells is indicated in brackets. Error bars indicate ± SEM. n.s., not signiﬁcant; ***P b 0.001.
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normal-appearing cells (Fig. 3D, right). Altogether these results suggest
that increased cell size is caused by hyperactivation of the mTORC1
pathway.
To evaluate if rapamycin could prevent the emergence of cytomegal-
ic and dysmorphic neurons, pregnant Depdc5+/− dams were treated
with rapamycin as described above. We focused the analysis on litter-
mate rats aged P11. At P11, cytomegalic dysmorphic neuronswere pres-
ent in Depdc5+/− (Fig. 3E, left), but not in Depdc5+/+ littermates.
Standard histological analysis of cortical sections from the rapamycin-
treated Depdc5+/− rats showed rapamycin rescued cortical abnormali-
ties (Fig. 3E, middle). Quantitative measurements revealed a signiﬁcant
reduction in cell size and Nissl aggregates after rapamycin treatment in
Depdc5+/− neurons (reduced from ~30%when comparedwith untreat-
ed Depdc5+/− neurons) (Fig. 3E, right). Thus, Depdc5 haploinsufﬁciency
results in enhanced cell size and dysmorphy of neurons that are
preventable by rapamycin treatment, demonstrating an mTORC1-
dependent mechanism.3.7. Changes in pyramidal cell electrophysiology in Depdc5+/− rats
We searched for possible spontaneous epileptic behavior in
Depdc5+/− rats, since heterozygous DEPDC5mutations cause seizures
in Human. A video-based approach revealed no clonic or convulsive
seizure-like behavior in young (P10 to P28), juvenile (5 to 11 week-
old) or adult (12 to 20 week-old) rats (Depdc5+/−, n= 18; Depdc5+/+,
n = 10). We did not detect neither seizure-like events nor interictal
activity by electroencephalogram in young, juvenile and adult rats
(Depdc5+/−, n= 12; Depdc5+/+, n = 9) (Supplementary data, Fig. 2).
In line with this result, we note that all studies on heterozygous global
knockout rodents of Tsc1 and Tsc2 also reported the absence of spontane-
ous seizures (Lasarge and Danzer, 2014), to the exception of one global
Tsc1+/−mouse model that displays ictal events during a short postnatal
window (bP19) (Lozovaya et al., 2014).
We asked whether Depdc5-deﬁciency could alter the intrinsic prop-
erties and excitability of single neurons using in vivo simultaneous
electrocorticographic (ECoG) and intracellular recordings of cortical
Fig. 4. Depdc5+/− neurons exhibit altered neuronal electrophysiological properties. (A) Anatomical reconstruction of neurobiotin-injected layer V pyramidal neurons (Depdc5+/+, n = 6;
Depdc5+/−, n = 10). (B) Left panel: Spontaneous intracellular activity of a layer V cortical neuron and ECoG signals from Depdc5+/+ and Depdc5+/− rats. Right panel: summary data of
spontaneous ﬁring rate and average membrane potential (Vm). (C) Left panel: Intracellular responses to 500 ms suprathreshold current pulses from a regular spiking slow-adapting
(RS-SA), a regular spiking fast-adapting (RS-FA) and an intrinsic bursting (IB) neuron. Right panel: relative proportion of neurons displaying RS-SA, RS-FA or IB intrinsic ﬁring proﬁles.
(D) Relationship between the intrinsic ﬁring proﬁle and the transfer function of cortical pyramidal neurons. Left panel: representative F–I relationships for two neurons (RS-SA and RS-
FA from Depdc5+/+ and Depdc5+/− rats, respectively). Right panel: summary data of current threshold and neuronal gain values highlighting the differences between the two
genotypes. Color-coding is as in panel C. Number of neurons is indicated in brackets. n.s., not signiﬁcant; *P b 0.05; **P b 0.01 (Student's t-test or Mann–Whitney test). Blue and red is
indicated for +/+ and +/- respectively (shown in panel B). Light blue, orange and brown is indicated in panel C.
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Depdc5+/− rats, with typical pyramidal morphology). Spontaneously,
neurons from Depdc5+/− rats were signiﬁcantly more hyperpolarized
and had a lower ﬁring rate (9 out of 13 neurons were silent) than
Depdc5+/+ rat's neurons (Fig. 4A and B). This discrepancywas not asso-
ciated with changes in passive properties since themembrane input re-
sistance and time constant were similar between Depdc5+/− and
Depdc5+/+ neurons (Supplementary data, Fig. 3). Furthermore, action
potential parameters, including voltage threshold, amplitude, maxi-
mum rate-of-rise and total width, were not signiﬁcantly different
(P N 0.05 for each parameter, Student's t test and Mann–Whitney
tests) between genotypes.
We next investigated the ﬁring patterns ofDepdc5+/− neurons in re-
sponse to current pulse injections.We recorded three classes of pyrami-
dal neurons with distinct ﬁring patterns: intrinsic bursting (IB), regular
spiking slow adapting (RS-SA) and regular spiking fast adapting (RS-FA)
(Fig. 4C, left). Pyramidal cells of Depdc5+/+ rats displayed a typical ratio
for these different ﬁring proﬁles: IB 13%, RS-SA 66% and RS-FA 20%
(Degenetais et al., 2002;Nunez et al., 1993). In contrast, the relative pro-
portion of RS-FA neuronswas considerably higher in Depdc5+/− rats: IB
15%, RS-SA 23% and RS-FA 61% (Fig. 4C, right). These divergences were
in line with differences in transfer functions, measured as the mean
ﬁring frequency induced by depolarizing current pulses of increasing in-
tensity. Theminimal current to induce ﬁring in RS-FA neuronwasmuch
higher and the slope of the transfer functionwas lower than that for RS-
SA neurons (Fig. 4D, left). With increased numbers of RS-FA neurons,
Depdc5+/− neuronswere on average signiﬁcantly less responsive to ex-
citatory inputs (Fig. 4D, right). We note however that cytomegalic neu-
rons observed in Depdc5+/− rat brains, which were not recorded here,
may have pro-epileptic properties, as suggested in humans (Abdijadidet al., 2015). Thus, Depdc5-deﬁciency impacts both the overall intrinsic
properties and excitability of cortical pyramidal neurons.
4. Discussion
Humans that carry heterozygous loss-of-function mutations of
DEPDC5 exhibit focal epileptic syndromeswith orwithout developmen-
tal brain corticalmalformations.We introduced loss-of-functionDepdc5
mutations in F344 rats to mimic human haploinsufﬁciency. This novel
knockout animal model shows Depdc5 is required for global growth
and embryonic viability. Heterozygous deletion of Depdc5 in rat leads
to brain cortical abnormalities with cytomegalic and dysmorphic phos-
phorylated rpS6-positive neurons due to upregulation of the mTORC1
pathway.
In vitro, Depdc5 represses the activity of the amino-acid sensing
branch of the mTORC1 pathway (Bar-Peled et al., 2013; Panchaud
et al., 2013). Thus, we assessed in vivo howmTORC1 signaling is affected
by Depdc5-deﬁciency. Deletion of both Depdc5 alleles induced an em-
bryonic lethality, observed from E14.5, preceded by global growth
delay, consistent with the ubiquitous expression of Depdc5 in whole
body. Rapamycin, a speciﬁc mTORC1 inhibitor, when administered
prenatally, rescued the growth defect and improved the survival of
Depdc5−/− embryos, providing evidence of a direct link between
Depdc5 and mTORC1 signaling cascade. We further demonstrated that
deletion of both alleles of Depdc5 produces increased phosphorylation
of mTORC1 downstream effectors associated with enlargement of
soma size of cultured rat embryonic ﬁbroblasts (REFs). Our data also
show that REFs derived from Depdc5−/− embryos did not repress
mTORC1 activity during amino acid starvation, conﬁrming mTORC1
senses amino acid levels via Depdc5. Altogether, both the rapamycin
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that Depdc5-deﬁciency leads to early developmental mTORC1-
dependant defects. Similar effects are described in global and condition-
al knockout mouse models of mTORopathies including Tsc1 (Anderl
et al., 2011; Ma et al., 2014) and Tsc2 (Way et al., 2012). We note, how-
ever that the phenotype ofDepdc5-deﬁcient rats is less severe since Tsc1
and Tsc2 rodent models succumb earlier, during mid-gestation (from
E9.5).
Lack of a single Depdc5 copy reﬂects the genotype of patients who
are heterozygous for DEPDC5mutations. In rats, such a loss induced al-
terations in the neuronal development including aberrant cortical lam-
ination, indicative of neuronal migration defects. Furthermore Depdc5
haploinsufﬁency also conduced to the presence, throughout the cortex
of Depdc5+/− rats (from age P11) of cells, resembling cytomegalic dys-
morphic neurons and balloon cells in FCD type II patients, which typical-
ly exhibit an increased cell soma size of 50–100% (Lim and Crino, 2013).
We furthermore demonstrated that these morphological changes were
due to mTORC1 pathway hyperactivity, and that prenatal administra-
tion of rapamycin was effective in preventing their apparition. Thus
this model shares neuropathological hallmarks with sporadic FCD type
II patients presenting dysmorphic cortical neurons (Baybis et al., 2004;
Miyata et al., 2004). Accordingly, phosphorylated rpS6-positive dys-
morphic neurons were also seen in postoperative brain tissue from a
FCD type II patient with a DEPDC5mutation (Scerri et al., 2015). These
brain pathological ﬁndings also parallel the phenotype in Tsc1 condi-
tional knockout mouse with enlarged dysmorphic neurons associated
with increased mTORC1 activity (Meikle et al., 2007). Similar to the
other Tsc1 and Tsc2 brain-speciﬁc knockout rodent models (Goto et al.,
2011;Meikle et al., 2008; Tsai et al., 2013), rapamycin treatmentwas ef-
fective in this model and improved the cortical abnormalities. This re-
sult conﬁrms an mTORC1-dependent mechanism leading to the
features reminiscent of FCD in heterozygous Depdc5+/− rats.
However, despite these developmental cortical abnormalities, we
did not detect spontaneous seizures in Depdc5+/− rats. In Depdc5+/−
F344 rats, as in most other Tsc1+/− and Tsc2+/− global knockout rodent
models, gene dosage effects may ensure that deletion of a single copy is
not sufﬁcient to trigger seizures. Therefore, we speculate that investiga-
tion of epileptic activity will necessitate viable homozygous animals
using conditional brain-speciﬁc knockout approaches, as done in other
studies with Tsc1 and Tsc2 rodent models (Bateup et al., 2013; Meikle
et al., 2007). Indeed, brain-speciﬁc conditional Tsc1−/− and Tsc2−/−
knockout mouse consistently exhibit spontaneous epileptic seizures.
We then asked if and how the deletion of Depdc5 could alter the
electrophysiological properties of cortical neurons. Intracellular record-
ings in Depdc5+/− rats revealed increased proportion of pyramidal
neurons with a peculiar ﬁring pattern (RS-FA type) consisting of
hyperpolarized membrane potentials and a response restricted to the
initial part of depolarizing current steps. The molecular cascade that
links Depdc5 to the regulation of the physiological neuronal types
remains to be addressed. Yet,we hypothesize that the increased propor-
tion of RS-FA type cells is plausibly caused by potentiation of potassium
(K+) channels activity through mTORC1 pathway activity. Accordingly,
it has been shown that elevated levels of mTOR increase K+ currents,
leading to neuronal electrical properties reminiscent of thosemeasured
in RS-FA neurons (Yang et al., 2012). Enhanced mTORC1 activity has
been shown to regulate neuronal excitability notably by direct actions
on ion channel expression (Lasarge and Danzer, 2014). Other genes as-
sociated with inherited focal epilepsies include a neuronal (Slack)
sodium-activated potassium channel subunit (KCNT1) as well as three
neuronal nicotinic acetylcholine receptor subunit genes (CHRNA4,
CHRNA2, CHRNB2). Therefore, it will be relevant to address whether
downstream effects of Depdc5-deﬁciency include direct or indirect ac-
tions on Slack potassium channels or the nicotinic receptors, underlying
a common pathway for familial focal epilepsies. Alternatively, Depdc5
may have a role in the physiological late differentiation of the various
subtypes of pyramidal neurons.5. Conclusions
This study highlights the critical role of Depdc5 in development,
and provides proof that Depdc5 inhibits mTORC1 signaling in vivo.
Depdc5−/− knockout rats exhibit several features common to other
mTORopathy rodent models, such as global growth delay, embryonic
lethality, mTORC1 upregulation and beneﬁt of rapamycin rescue.
Depdc5+/− rats display developmental neuropathological abnormalities
such as cytomegalic dysmorphic phosphorylated rpS6-positive neurons
and brain cortical dyslamination, reminiscent of those induced by
DEPDC5mutations in humanswith FCD type II. These neuropathological
abnormalities appeared during the development and were rescued by
prenatal rapamycin treatment. Thus, this study provides evidence that
rapamycin can induce signiﬁcant physiologic improvement in vivo in a
model of Depdc5-deﬁciency. The poor efﬁcacy of conventional antiepi-
leptic drugs (Baulac et al., 2015; Picard et al., 2014) imposes a switch
to more effective drugs with targets based on a better understanding
of the physiopathological mechanisms involved. The mTORC1 inhibitor
rapamycin, which reduces seizures in TSC patients with intractable ep-
ilepsy (Wiegand et al., 2013), may serve as a starting point to develop
novel molecules to treat patients with diverse mTORopathies.
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